Category
Biologics & Advanced Therapies
Modern targeted treatments for moderate-severe IBD
Skyrizi vs Remicade for Ulcerative Colitis: Patient Guide
Skyrizi and Remicade represent two very different approaches to treating moderate-to-severe ulcerative colitis. Remicade has been the anti-TNF standard for UC since the mid-2000s. Skyrizi is a newer IL-23 p19-selective biologic that gained UC approval in June 2024 based on INSPIRE and COMMAND trials. Patients commonly compare these drugs when starting a first biologic or considering alternatives after Remicade has lost effect. This guide walks through the skyrizi vs remicade ulcerative colitis decision.
Skyrizi vs Remicade for Crohn's Disease: Which Is Better?
Skyrizi and Remicade represent two very different eras of Crohn's biologic therapy. Remicade (infliximab) has been the anti-TNF workhorse since its approval in the late 1990s. Skyrizi (risankizumab) is a newer IL-23 p19-selective biologic that gained Crohn's approval in 2022 and has quickly gained market share. Patients often compare these drugs when starting biologic therapy for the first time or when weighing alternatives after Remicade has lost effect. This guide walks through the evidence for the skyrizi vs remicade crohn's decision.
Skyrizi vs Omvoh for Ulcerative Colitis: A Comparison
Skyrizi and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe ulcerative colitis. Omvoh gained UC approval first in October 2023 based on LUCENT-1 and LUCENT-2. Skyrizi followed in June 2024 based on INSPIRE and COMMAND. Patients comparing these two within-class UC options often weigh maintenance dosing, bowel urgency outcomes, and trial design. This guide walks through the skyrizi vs omvoh ulcerative colitis comparison.
Skyrizi vs Omvoh for Crohn's Disease: A Comparison
Skyrizi and Omvoh are both IL-23 p19-selective biologics for moderate-to-severe Crohn's disease. Skyrizi gained Crohn's approval in June 2022 based on the ADVANCE, MOTIVATE, and FORTIFY trials. Omvoh gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these two within-class options often weigh maintenance dosing, trial design, and GI familiarity with each drug. This guide walks through the skyrizi vs omvoh crohn's comparison.
Skyrizi vs Humira for Ulcerative Colitis: What to Know
Skyrizi and Humira are two AbbVie biologics for moderate-to-severe ulcerative colitis, but they work through very different mechanisms. Humira is the established anti-TNF standard with more than a decade of UC experience. Skyrizi is an IL-23 p19-selective biologic that gained UC approval in June 2024 based on the INSPIRE induction and COMMAND maintenance trials. For UC patients choosing between these drugs, the decision often comes down to mechanism, administration preferences, and expected long-term safety. This guide walks through the skyrizi vs humira ulcerative colitis decision.
Skyrizi vs Humira for Crohn's Disease: Comparing Options
Skyrizi and Humira are both AbbVie biologics for moderate-to-severe Crohn's disease, and they represent very different mechanisms. Humira is the long-established anti-TNF standard with more than two decades of use in IBD. Skyrizi is a newer IL-23 p19-selective biologic that gained Crohn's approval in 2022 and has quickly become a prescribing favorite. For patients weighing a first-line biologic, the skyrizi vs humira crohn's decision often comes down to mechanism, administration preferences, and data from anti-TNF experienced cohorts. This guide walks through the evidence Crohn's patients need to discuss with their gastroenterologist.
Skyrizi vs Entyvio for Ulcerative Colitis: A Comparison
Skyrizi and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs but through very different mechanisms. Skyrizi is an IL-23 p19-selective biologic that gained UC approval in June 2024. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing its superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or are looking for alternatives to anti-TNF therapy. This guide walks through the skyrizi vs entyvio ulcerative colitis comparison.
Skyrizi vs Entyvio for Crohn's Disease: A Patient Guide
Skyrizi and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, and they take very different approaches to quieting gut inflammation. Skyrizi is an IL-23 p19-selective biologic that acts on the immune system more broadly while still avoiding TNF blockade. Entyvio is gut-selective and acts almost exclusively on the intestines. Both are increasingly common choices for patients who have failed an anti-TNF or want to avoid systemic immunosuppression from the start. This guide walks through the evidence Crohn's patients need for the skyrizi vs entyvio crohn's decision.
Simponi vs Tremfya for Ulcerative Colitis: Comparing Biologics
Simponi and Tremfya represent two very different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Tremfya (guselkumab) is an IL-23 p19-selective biologic approved for UC in September 2024 based on QUASAR and ASTRO. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with distinctive induction flexibility. This guide walks through the simponi vs tremfya ulcerative colitis comparison.
Simponi vs Stelara for Ulcerative Colitis: How They Compare
Simponi and Stelara are two subcutaneous biologics for moderate-to-severe ulcerative colitis that work through fundamentally different mechanisms. Simponi (golimumab) is an anti-TNF biologic. Stelara (ustekinumab) is an IL-12/23 inhibitor. Patients comparing these drugs often weigh established TNF-alpha blockade against the IL-12/23 pathway, particularly when considering first-line therapy or switching after anti-TNF failure. This guide walks through the simponi vs stelara ulcerative colitis decision.
Simponi vs Skyrizi for Ulcerative Colitis: A Patient Guide
Simponi and Skyrizi represent two different generations of biologic therapy for moderate-to-severe ulcerative colitis. Simponi (golimumab) is a subcutaneous anti-TNF biologic that has been a UC option since 2013. Skyrizi (risankizumab) is an IL-23 p19-selective biologic that gained UC approval in June 2024 based on INSPIRE and COMMAND. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and safety data. This guide walks through the simponi vs skyrizi ulcerative colitis comparison.
Simponi vs Remicade for Ulcerative Colitis: Key Differences
Simponi and Remicade are two anti-TNF biologics for moderate-to-severe ulcerative colitis that take different administration routes. Simponi (golimumab) is a subcutaneous injection. Remicade (infliximab) is an intravenous infusion. Both block TNF-alpha, so their mechanisms are closely related, but the administration difference and dose escalation options shape the practical comparison. This guide walks through the simponi vs remicade ulcerative colitis decision.